## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Mashiach Nissim				2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [ LPTX ]					(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2023						Officer ( below)	give title	Other (s below)	pecify	
C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
(Street)	IDGE M	ΙA	02141									Form fil Person	ed by More	than One Repor	ting
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, D	isposed o	of, or Be	neficially	Owned			
Date			action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			Beneficia Owned Fo	s Form (D) o ollowing (I) (In	Form: Direct D) or Indirect I) (Instr. 4)	'. Nature of ndirect Beneficial Ownership				
						Code V	Amount	(A) o (D)	r Price	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any		Code	ansaction Derivative ode (Instr. Securities		Expiration Date of So (Month/Day/Year) Und Deri		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$0.34	03/31/2023		A		150,000		(1)	03/31/2033	Common Stock	150,000	\$0	150,000	D	

## Explanation of Responses:

1. The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023 for so long as the reporting person continues to be a director, consultant or service provider of the Company until the Option is fully vested.

/s/ Douglas E. Onsi as attorney-04/04/2023 in-fact for Nissim Mashiach

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.